Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:
Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead’s acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead’s exposure to cell therapy and noncell therapy in oncology.
A quick look at the price chart below shows us that the stock is down 8% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 8.8, which means that it remains undervalued.
Superinvestors who currently hold positions in the company include:
Dodge & Cox – 37,174,777
Jim Simons – 9,082,069
John Rogers – 2,413,576
Cliff Asness – 1,229,885
Ken Griffin – 664,223
Israel Englander – 335,554
David Katz – 329,171
Joel Greenblatt – 85,355
Paul Tudor-Jones – 82,875
Ray Dalio – 43,138
Murray Stahl – 11,017
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple: